The Journal of Pathology · 2005 · 48 citations · 23 references
MedicineCancer BiologyOncologyCell SignalingNeoplasiaSignal TransductionAngiogenesisAngiogenesis In CancerCancer Cell SignalingGrowth Factor SignalingFibroblast Growth Factor Receptor 3 (Fgfr3) DisordersFibroblast Growth Factor Receptor SignalingHypoxic MicroenvironmentVascular Endothelial Growth FactorVascular Endothelial Growth Factor Receptor SignalingVascular Endothelial Growth Factor ReceptorsVascular Endothelial Growth Factor Signaling
The expression of fibroblast growth factors (FGF1 and FGF2) and their receptors has been reported in a variety of human neoplasms, including haematological neoplasia. Fibroblast growth factors can promote tumour growth directly, or indirectly through promoting the growth of vessels. In the present study, we evaluated the expression of FGF1 and FGF2 as well as FGF receptors 1-4 (FGFR1-FGFR4) in 39 cases of Hodgkin's lymphoma, including all subtypes, as well as Hodgkin's lymphoma cell lines. FGF1 and FGF2 and their receptors FGFR2-FGFR4, but not FGFR1, were found to be expressed by the malignant cells in the majority of cases. Interestingly, only FGFR3, but none of the FGFs or the other FGFRs, was expressed by the Hodgkin's lymphoma cell lines. This indicates that only FGFR3 is constitutively expressed by Hodgkin's lymphoma cells, whereas FGFs and the other FGFRs are induced in vivo. Culture of the Hodgkin's cell lines under conditions of hypoxic stress could induce vascular endothelial growth factor (VEGF) but not FGF expression. FGFs, in contrast to VEGF, might be expressed in response to paracrine stimuli. In situ hybridization did not reveal FGFR3 gene amplification or translocation as the cause of constitutive FGFR3 expression, as has been shown in a subset of multiple myeloma. FGFR3 might be expressed as part of the Hodgkin's cell phenotype. The demonstration of widespread expression of FGFs and some of their receptors in Hodgkin's lymphoma suggests that FGFs are important for sustaining growth of the lymphoma and suggests that anti-FGF antibodies could be used as an adjuvant treatment.
23
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
David Cappellen, Catherine De Oliveira, David Ricol et al. · Nature Genetics · 1999 · 705 citations
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
Álvaro Aguayo, Hagop M. Kantarjian, Taghi Manshouri et al. · Blood · 2000 · 658 citations
Medicine, Hematology, Oncology +14
Marta Chesi, Elena Nardini, Leslie A. Brents et al. · Nature Genetics · 1997 · 647 citations